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Abstract
The large-scale use of antivirals during influenza pandemics poses a significant selection pressure for drug-resistant
pathogens to emerge and spread in a population. This requires treatment strategies to minimize total infections as well as
the emergence of resistance. Here we propose a mathematical model in which individuals infected with wild-type influenza,
if treated, can develop de novo resistance and further spread the resistant pathogen. Our main purpose is to explore the
impact of two important factors influencing treatment effectiveness: i) the relative transmissibility of the drug-resistant
strain to wild-type, and ii) the frequency of de novo resistance. For the endemic scenario, we find a condition between these
two parameters that indicates whether treatment regimes will be most beneficial at intermediate or more extreme values
(e.g., the fraction of infected that are treated). Moreover, we present analytical expressions for effective treatment regimes
and provide evidence of its applicability across a range of modeling scenarios: endemic behavior with deterministic
homogeneous mixing, and single-epidemic behavior with deterministic homogeneous mixing and stochastic heteroge-
neous mixing. Therefore, our results provide insights for the control of drug-resistance in influenza across time scales.
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Introduction
Rapid antigenic evolution in the influenza virus increases the
likelihood of emergence of novel strains, against which little to no
immunity may exist in the host population [1–4]. In this scenario,
if vaccines are not yet available or non-pharmaceutical interven-
tions have limited impact on disease containment, antiviral
treatment plays a crucial role in the control of the disease [3,5–
7]. A critical constraint in the deployment of antivirals agents (e.g.,
M2 inhibitors and neuraminidase inhibitors [8]) is the evolution of
highly transmissible drug-resistant mutants [9]. Resistance de-
creases the effectiveness of chemotherapy in infected patients,
prolonging recovery or leading to outright treatment failure [10].
Epidemics of untreatable strains have the potential to cause major
morbidity and mortality [11–14], with significant economic costs
for both the individual and for society writ large [15].
Consequently, public health policy has a growing need to
understand the key factors that lead to the rise and spread of
resistance, and to devise strategies that amplify the effectiveness of
existing drugs, while halting the spread of resistance [16–19].
In addition to important precautionary measures, such as
improvement of hospital counter-infection methods and regulation
of antiviral use, mathematical models can be used to explore
plausible competition scenarios between sensitive and resistant
strains and the impact of treatment strategies on these dynamics
[17,19–22]. Previous models of the development of resistance of
influenza to antiviral agents have focused on efforts to minimize
the fraction of drug-resistant infections during an epidemic
outbreak [5–7,17] and to give recommendations that inform
policy [8,15,18,23–25]. However, the study of the long-term
(endemic) dynamics of drug-resistance has received less attention
[26].
The present work assesses the effectiveness of treatment at
minimizing the total number of infections while halting the spread
of drug-resistance, both from an endemic and a single-epidemic
perspective. We focus our attention on two points: i) the relative
transmissibility of the drug-resistant strain with respect to the wild-
type (drug-sensitive) strain, and ii) the frequency of de novo
resistance. Point i) is related to the fitness cost associated with
the evolution of drug resistance, reflected in a reduced transmis-
sibility of the drug-resistant pathogen relative to its wild-type
counterpart [8,27]. Recent evidence has demonstrated, however,
that this reduction in fitness may be limited due to compensatory
mutations which can restore fitness without loss of resistance-
conferring genes [9,28]. Point ii) represents the probability that
treatment leads to resistance within the treated host (de novo). Both
quantities are crucial in the population dynamics of drug-
resistance, specially due to their variability within different
epidemiological settings [8]. Nonetheless, their combined effect
on the effectiveness of treatment regimes during influenza
pandemics is not fully understood [5].
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We build on a previous model [17] to examine these issues in
the long-term (endemic disease prevalence) as well as in the short-
term (single-epidemic). Lipsitch et al. [17] observed that interme-
diate levels of antiviral use are indicated to reduce the attack rate
during an influenza pandemic. Complementing these results, we
find that to effectively reduce the endemic levels of the wild-type
and resistant strains, treatment regimes (i.e., treated fraction)
should be at intermediate levels if the resistant strain is highly
transmissible and de novo resistance is rare. However, if resistance
comes with a high fitness cost and de novo resistance is frequent,
then higher levels of antiviral use may be preferable. In the single
epidemic case we compare our optimal treatment regime with that
of [17], showing that their relative effectiveness also depends on
the strains’ relative transmissibility and the frequency of de novo
resistance. Moreover, we demonstrate the applicability of our
optimal treatment regimes by evidencing its effectiveness at
quelling the spread of resistance when considering the effects of
the stochasticity inherent to the transmission dynamics and the
complex contact structure in the population.
Methods
Model Formulation
We extend a version of the model in [17] to include
demography (see Figure 1). Susceptible hosts, S, enter the
population at a per-capita rate m and die at rate equal to m,
keeping the total population size, N , constant. Susceptible
individuals can be infected by pathogens either sensitive or
resistant to the available antiviral (this model does not include
superinfection with both strains). A fraction r of patients infected
with the wild-type strain are treated, and a fraction c of those
treated develop resistance de novo. Therefore, individuals infected
with the wild-type strain are either untreated (Iu), effectively
treated (It), or resistant to treatment (Ir). Infection with a resistant
strain is either developed de novo or acquired from another
resistant-infected individual. Susceptible individuals become
infected at a rate proportional to the densities of susceptible and
infected individuals, and to the transmission rates of each class,
bu, bt, and br, respectively. Untreated, treated, and resistant
infected individuals recover at per-capita rates cu,ct, and cr,
respectively. We assume no disease-induced mortality, and that the
pathogen induces sterilizing immunity [21,29].
The relative transmissibility of the resistant strain is defined as
w~br=bu§0. Successfully treated individuals: 1) are not more
infectious: bt~mbu, where m[½0,1 is the reduction in viral
shedding [16,30,31], and 2) recover faster: ct~cuzt, where tw0
is the increase in recovery rate [8,16,32].
The ordinary differential equation (ODE) model describing
these dynamics is
dS
dt
~m{(hwzhrzm)S ð1Þ
dIt
dt
~hwSr(1{c){(cuztzm)It ð2Þ
dIu
dt
~hwS(1{r){(cuzm)Iu ð3Þ
dIr
dt
~hrSzhwSrc{(crzm)Ir ð4Þ
dR
dt
~(cuzt)ItzcuIuzcrIr{mR ð5Þ
with forces of infection hw~buIuzmbuIt and hr~wbuIr. Note, we
are modeling densities (i.e., N~1). In what follows, let sx be the
total per-capita rate out of class Ix, i.e., st~cuztzm, su~cuzm,
and sr~crzm.
Reproduction numbers. The basic reproduction number,
R0, is the average number of secondary cases produced by a
typical infected individual in a completely susceptible population.
We find R0 for each strain using the Next Generation Operator
(NGO) method [33]. The non-zero eigenvalues of the NGO
matrix
Rw0~bu
mr(1{c)
st
z
(1{r)
su
 
, ð6Þ
Rr0~bu
w
sr
, ð7Þ
are the reproduction number of the wild-type and resistant strains,
respectively. Detailed derivations can be found in the Supporting
Information (Text S1).
Results
Fixed Points and Bifurcation Analysis
The system (1)–(5) has three fixed points (FPs): 1) a disease free
equilibrium (DFE); a FP where only the resistant strain persists
(RFP); and a coexistence FP in which both strains coexist (CFP).
Conceptually, these FPs represent: 1) eradication of both resistant
and wild-type strain, eradication of the wild-type strain when
treatment and/or relative transmissibility are high enough to allow
persistence of the resistant strain; and coexistence of both strains
due to low treatment and/or low fitness of the resistant strain,
where typically the resistant strain persists at low levels. The FPs
are:
Figure 1. Compartmental Model for Eqs. (1)–(5).
doi:10.1371/journal.pone.0059529.g001
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DFE:
fS1,I1t ,I1u ,I1r g~f1,0,0,0g ð8Þ
RFP:
fS2,I2t ,I2u ,I2r g~
1
Rr0
,0,0,
m
wbu
(Rr0{1)
 
ð9Þ
CFP:
fS3,I3t ,I3u ,I3r g~
1
Rw0
,
1{cð Þrm
s
jY,
1{rð Þm
su
jY,cr
m
s
Y
 
ð10Þ
where
j :~1{
Rr0
Rw0
and Y :~
Rw0{1
Rw0{(1{cr)R
r
0
: ð11Þ
The recovered class fraction in each case is given by
R~1{S{It{I

u{I

r . Comparing the susceptible steady states
in (9) and (10) suggests that for the RFP, prevalent infections are
attributable to the resistant strain, whereas for the CFP, the
reproduction number of the wild-type strain determines how
prevalent the disease is.
To be biologically significant (BS) the steady states have to lie in
the set
D~f(S,It,Iu,Ir,R) [ ½0,15DSzItzIuzIrzR~1g:
The RFP is BS if Rr0§1. For the CFP, Rw0§1 must hold so that
S3ƒ1. This also implies that the numerator ofY in (11) is positive.
For I3r to be non-negative, the denominator of Y must be positive,
i.e., Rw0w(1{cr)Rr0, which implies Rw0 =Rr0w1{cr. For I3t and I3u
to be non-negative Rw0 =R
r
0§1w1{rc must hold. Therefore, the
CFP is BS if
Rw0§1 and R
w
0§R
r
0: ð12Þ
Thus, the two strains coexist if the wild-type strain is
transmissible enough to be able to spread, and also more
transmissible than the resistant strain.
Stability of fixed points. For the stability analysis of the FPs
we study the eigenvalues of the matrix in the linearized system
around the FPs: equilibria that have eigenvalues with negative real
part are stable, whereas equilibria that have eigenvalues with
positive real part are unstable [34]. We present here the results of
the analysis; detailed analytic derivations can be found in the Text
S1.
As expected, the DFE is globally stable if Rw0v1 and Rr0v1.
The RFP is locally stable if Rr0wRw0 . While determining the
stability of the CFP is not analytically tractable, (12) states that the
CFP is BS if Rw0§1 and Rw0§Rr0. Thus, the conditions in (12)
imply that neither the DFE nor the RFP are stable. We then
conjecture that the CFP is BS and globally stable if (12) holds.
Epidemiological arguments and numerical integrations support
this hypothesis.
Bifurcation analysis. Depending on Rr0 and R
w
0 , the system
has one, two, or three BS FPs. Figure 2 features all four stability
regions described above in the (w,r) and the (Rw0 ,R
r
0) parameter
space. The boundary of these regions can be found by solving
Rw0 (r
)~Rr0,R
w
0 (r
1)~1, and Rr0(w
1)~1, yielding
w1~
sr
bu
, r1~
(bu{su)st
bust{mbu(1{c)su
, ð13Þ
and
r(w)~
(sr{wsu)st
sr½st{m(1{c)su : ð14Þ
The boundaries are shown in Figure 2, where r is the red-
dashed line, r1 is the dashed and horizontal line, and w1 is the
dashed and vertical line. The intersection of these curves (black
dot) represents the overall disease threshold: any increase in w or
decrease in r away from this intersection would result in an
epidemic. Moreover, Eq. (13) shows that, for appropriate
parameter values, increasing t or decreasing m, decreases the r-
coordinate (r1) of the overall disease threshold point. Thus,
increasing the recovery rate or decreasing the transmission rate of
those treated, represents an epidemiological trade-off: it jointly
expands the ‘‘DFE’’ and the ‘‘Resistance’’ stability regions, making
it more likely for the system to either stay disease-free or give rise
to prevalent resistance (see Figure S4, S5, S6, S7, S8 in Text S1 for
details).
Optimal Treatment Regimes
The main goal of this work is to derive treatment regimes (i.e.,
treated fractions) that minimize the wild-type infections while
restraining the spread of resistance. From the CFP in (10), it is
clear that for very low treatment levels, the wild-type strain is
prevalent in the population, and the resistant strain prevalence
stays at minimal levels [10], i.e., Rw0 (r~0)wRr0. Additionally,
treatment will reduce the viral shedding (mbuvbu) and increase
Figure 2. Stability regions in the (r, w) and (Rw0 ,R
r
0) parameter
space. Coexistence 2FP (CFP stable, DFE unstable); Coexistence 3FP
(CFP stable, DFE unstable, RFP unstable); Resistance (DFE unstable, RFP
stable). When the system crosses any of the region boundaries it
experiences a transcritical bifurcation.
doi:10.1371/journal.pone.0059529.g002
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the recovery rate by t, implying that LRw0 =Lrv0. Thus, treating a
larger proportion of the population will reduce the number of
wild-type infected. However, it will also increase the number of de
novo resistant cases, as well as the pool of susceptibles for the
resistant strain to spread in.
These observations intuitively suggest that an effective treat-
ment strategy should minimize Rw0 by increasing r, while keeping
Rw0§Rr0. Formally,
r~ argmin
r
Rw0 (r), s:t: R
w
0§R
r
0: ð15Þ
Since Rr0 does not depend on r (Eq. (7)), and assuming
Rw0 (r~0)wRr0, (15) can be solved by reducing Rw0 until
Rw0 (r)~R
r
0. This equality yields r
 as in (14), a linearly decreasing
function of the relative transmissibility, w (see Figure 2).
However, (15) is inadequate since it does not consider the fitness
advantage that development of de novo resistant cases give to the
resistant strain. As R0 is the expected number of new cases
produced by a typical infected person in a susceptible population,
this quantity can be considered a measure of the fitness of a
pathogen at the population level. Additionally, in our model, c is
directly related to the within-host fitness of the resistant pathogen.
The overall fitness of the resistant strain is the added contributions
of the fitness at the population and the within-host level. To estimate
this overall fitness, assume, for the sake of clarity,
si~s, Vi[fu,t,rg. Let also Inr and Inw~InuzInt be the number of
resistant and wild-type cases in the nth ‘‘epidemic generation’’
(with duration approximately 1=s) in a predominantly susceptible
population. Defining Fr~I
nz1
r =I
n
r and Fw~I
nz1
w =I
n
w as the
overall fitness of the resistant and wild-type strains, respectively,
we obtain (see Text S1 for details):
Fw~R
w
0H(r
{r) and Fr~Rr0z
rc
1{rc
Rw0H(r
{r), ð16Þ
where H(x) is the Heaviside step function (H(x)~1 if x§0, and
H(x)~0 otherwise), i.e., if rwr, the wild-type strain goes extinct.
It is then clear that Fr has an additional contribution from the de
novo cases. More importantly, from the sole comparison of the
reproduction numbers we cannot infer properly which strain will
dominate, nor can we devise effective treatment regimes.
A more appropriate way to optimize the treatment regime is
attained by focussing on the fixed points (FPs). The system has two
FPs where the disease is endemic (RFP and CFP). On the one
hand, if the CFP is stable, the optimal treatment regime, re, is
defined as the fraction treated that yields the minimum number of
wild-type infected, while the resistant is kept at lower endemic
levels than the wild-type. Formally,
re~ argmin
r
(I3w), s:t: I
3
w§I
3
r ð17Þ
where I3w:I
3
uzI
3
t . The regime re can then be found by solving
for r in I3w~I
3
r (see Eq. (19)).
On the other hand, if the RFP is stable, then treatment will have
no effect on the prevalence of the resistant strain since I2r is not a
function of r. Two scenarios are then possible: (A) I3r (re)vI2r , or
(B) I3r (re)§I2r . An assessment of these two scenarios yields our
definition of overall optimal treatment regime ropt: if (A) is true,
ropt will minimize the endemic levels of the wild-type strain, while
keeping the resistant strain at comparatively low levels; if (B)
holds, ropt will transition the system to the RFP stability region.
Hence, in case (A) it is best to maintain the system within the CFP
limits, whereas in (B) the RFP will be preferred. The latter can be
achieved by increasing r beyond r. Formally,
ropt~
re if I
3
r (re)vI2r (A)
r,1 if I3r (re)§I2r (B)
(
,
We now show that conditions (A) and (B) can be expressed in
terms of our two key parameters: relative transmissibility, w, and
the frequency of de novo resistance, c. To find re we solve for r in
I3w~I
3
r , or,
Rw0~R
r
0zR
w
0
sustcr
(1{c)rsusrz(1{r)stsr
 
: ð18Þ
Within the CFP limits, (19) indicates when the overall fitness of
both strains are equal (notice the similarity of the left hand side
and the right hand side of (19) with, respectively, Fw and Fr in (16),
when si~s,Vi[fu,t,rg). The explicit expression for re is given in
the Text S1. Noteworthy, re is the only value of r in (0,r
) for
which I3w~I
3
r . This claim is justified as follows: I
3
w(r) is a
monotonically decreasing function of r in (0,r), with
I3w(0)wI3r (0) and Iwr (r)vI3r (r). Additionally, I3r (r) is either
increasing or concave in (0,r) (see Figure 3). In both cases, I3w and
I3r intersect at only one point (green dots in Figure 3). See Text S1
and Figure S10 for analytic details.
It is easy to show that I3r (r
)~I2r (gray dots in Figure 3).
However, also I3r (rr)~I
2
r , where
rr~
Rr0{1
Rr0c
: ð19Þ
Then, if 0vrrvr, the term rr represents the treatment
regime within the region of coexistence (CFP) for which the
resistant strain is as prevalent as in the resistant-only stability
region (RFP) (red dot in Figure 3). Additionally, it can be deduced
from (20) that
rrvr[Rr0v(1{r
c){1: ð20Þ
In the Text S1 we show that when (21) holds, I3r (r) is concave
for r[(0,r). The concavity of I3r (r) means, biologically, that the
resistant strain prevalence is sustained largely by de novo resistant
cases. Put differently, Rr0 is not large enough for the resistant strain
to self-sustain high levels of prevalence in the absence of treated
wild-type infected.
Recalling that I3r (rr)~I
2
r and I
3
r (r
)~I2r , if I
r
r (r) is concave for
r[(0,r) and rrvrevr, then I3r (re)wI2r (condition (B)),
indicating that the RFP is preferred over the CFP (solid curves
in Figure 3). Furthermore, condition rrvrevr reduces to
rrvre given that I3w(r)~I
3
r (r) for r[(0,r
). If instead rrwre,
then condition (A) applies and keeping the system in the CFP
while applying a treatment regime re will be the best option
(dashed curves in Figure 3). These observations along with
expression (20) allow to restate conditions (A) and (B), and
therefore the optimal treatment, in terms of w and c as
Resistant Strain Traits and Effective Treatment
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ropt~
re
r,1ð 
 if Rr0{1
Rr0c
wre
if
Rr0{1
Rr0c
vre
(A)
(B)
In case (A), which corresponds to a high w and low c scenario,
the CFP is stable with the wild-type and the resistant strains kept at
low levels. In case (B) (i.e., low w and high c), shifting the stability
to the RFP is preferable since only the resistant strain will persist at
low levels (see Figure 3). In other words, if the resistant strain
features high relative transmissibility and resistance is rare, the best
treatment regime would be at intermediate levels (re); whereas if
the opposite holds true, treating a larger fraction (wr) of the
infected population is preferred.
Recalling re and r
 are found from (19) and Rw0~R
r
0,
respectively, and noticing that as c?0z expression (19) reduces
to Rw0~R
r
0, we conclude that re?r
 as c?0z. For this reason,
when c is small v*10{2
 
r&rezE, with 0vE%re, becomes a
good treatment strategy if (A) holds. Moreover, as c?0z, it is
expected that (A) holds, at least in the epidemiologically
interesting cases where Rr0 will likely be greater than
(1{cre)
{1
*> 1 (i.e., the resistant strain can emerge and spread
in the population). In conclusion, when c is small, then r~r{E is
a good treatment regime to minimize both the wild-type and the
resistant strains (green bands in Figure 4).
Despite the large uncertainties in the frequency of patients that
develop de novo resistance [8], c can be assumed to be relatively
small. Figure 4 evidences how, for c~0:002 (as in [17]), r~r{E
is the optimal treatment fraction: it diminishes the prevalence of
the sensitive strain as much as possible, while hindering the
emergence of the resistant strain. For low levels of treatment the
CFP is stable: the wild-type strain prevails and the resistant strain
Ir2
Iw3
Ir3
0.0 0.2 0.4 0.6 0.8 1.00.0000
0.00002
0.00004
0.00006
0.00008
0.0001
Treatment Fraction
In
fe
ct
ed
Pr
ev
al
en
ce
Figure 3. The two possible monotonicity behaviors of I3r (r). In black, I
3
r (r) is concave for R
r
0(w)v(1{rc)
{1 (solid lines) (w~0:42), and
monotonically increasing for Rr0(w)§(1{rc)
{1 (dashed lines) (w~0:55). Red lines are the corresponding I3w(r) curves. The x-values of the green and
gray dots represent re and r
 , respectively, while the x-value of the red dot represents rr. As w (or Rr0) increases, the red dot moves rightward,
surpassing the green dot (rr~re), and eventually surpassing the gray dot as well (rr~r
). At this point, the system displays a transcritical bifurcation
between the CFP and the RFP. Other parameters: cr~cu~0:2, t~0, bu~0:5, m~0:34, c~0:2. A large value of c was used to magnify the difference
between the two cases.
doi:10.1371/journal.pone.0059529.g003
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(I3r ) remains at low levels. As soon as rwr&re, the resistant
strain out-competes the wild-type strain. Expectedly, as treatment
further reduces the infectious period (i.e. larger t, dashed lines),
increasing treatment reduces the wild-type strain prevalence more
effectively. In this case, the optimal levels of treatment are lower. A
similar behavior is obtained when, instead of increasing t, we
reduce m (reduction of viral shedding due to treatment).
Frequency of de novo resistance and endemic levels of
resistance. We have shown how the frequency of de novo
resistance, c, plays a crucial role in devising effective treatment
strategies. In addition, we find that smaller values of c lead to more
abrupt transitions from wild-type to resistant strains. In other
words, the smaller the probability of developing de novo resistance,
the faster the RFP gains stability when the system is close to the
threshold Rw0~R
r
0 (Figure 5). Thus, for small c, the system
becomes more sensitive to variations in r, t, m, and w near this
threshold. This represents a potentially dangerous scenario: if the
likelihood of de novo resistance is small, a policy-maker might
underestimate the prospects of resistance emergence and, conse-
quently, increase treatment levels to eradicate the wild-type strain.
However, if treatment is increased above r, an abrupt transition
may occur to a state where only resistant strains persist.
Mathematically, this ‘‘abrupt transition’’ can be justified as
follows: if c%1, then Rw0{(1{cr)Rr0&Rw0{Rr0; hence, when
Rr0&R
w
0 , there is a ‘‘singularity’’ for I
w
3 and I
r
3 in the CFP (10).
Biologically, it is clear from (16) that lim c?0zFr~R
r
0 and
lim c?0zFw~R
w
0 . That is, as c?0
z, the reproduction numbers
become the overall fitnesses of the strains, and Rw0~R
r
0 represents
the condition for which both strains are equally fit. Thus, the
resistant strain outcompetes the wild-type strain as Rr0 surpasses
Rw0 .
The Single Epidemic Case
Frequently, public health programs and interventions are
designed to prevent the emergence of drug resistance within a
single epidemic. To address this issue, we model a closed
population (i.e., m~0 in model (1)–(5)), and examine again the
role of i) the relative transmissibility (w) and ii) the frequency of de
novo resistance (c) on the effectiveness of treatment regimes. In this
Ir2
Iw3
Ir3
0.0 0.2 0.4 0.6 0.8 1.0
0.00000
0.00005
0.00010
0.00015
Treatment Fraction
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ct
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Figure 4. Effectiveness of r for c~0:002 and Rr0w(1{rc)
{1. Prevalences I2r and I
3
r are depicted in black and I
3
w in red, for two different
treatment recovery benefits (t~0:1, solid; t~0:8, dashed). The RFP is unstable for rvr (blue dashed line). Strain dominance transition at re&r
(vertical dashed lines). Optimal treatment regimes (r{E) in green bands. Parameters: m~4:6|10{5, cu~cr~0:2, bu~0:5, m~0:34, w~0:6 (see also
Figure S9).
doi:10.1371/journal.pone.0059529.g004
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assessment we focus on the final epidemic size (FS), defined as the
proportion of the population infected during the epidemic. As in
[17], we introduce the following correction to our numerical
integrations: if Ir(t)v1 then Ir(t)~0. This prevents spurious
results induced by the transmission of ‘‘non-cases’’ (since Ir(0)~0,
initially Ir(t) can only increase due to de novo resistant cases; given
that Ir(t) is continuous in the ODE framework, the condition
above avoids that a fraction of a de novo resistant case can cause a
direct resistant infection). Throughout this section the following
parameters are fixed: N~5|105, m~0:34, cr~cu~0:2, t~0:1,
Ir(0)~It(0)~0 and Iu(0)~1.
Figure 6 shows a feature demonstrated previously [6,17,22]: the
existence of an ‘‘optimal’’ level of treatment for which the total FS
is minimized. We can readily see this minimum is a function of c:
as c increases, the dip in the combined FS curve vanishes.
Furthermore, the treatment regimes that minimize the total FS,
are not optimal in terms of avoiding the emergence of resistance.
Let rmin~ argminrFS(r). We find that r
vrmin, where as
before r satisfies Rw0 (r
)~Rr0. That is, the minimum in the FS is
reached when resistance has already significantly spread in the
population. Additionally, Figure 6 shows that for larger c
(diamond curves), r represents a value of the treatment fraction
for which the resistant strain has already spread considerably
throughout the population. This suggests that, as in the endemic
case, the effectiveness of r depends on the frequency of de novo
resistance: as c increases, the validity of r becomes compromised
(notice similarity in black curves of Figures 5 and 6).
Notice also in Figure 6 that the epidemic is eradicated if r
exceeds r1 (Eq. (13)), where Rw0 (r
1)~1. That is, when the
treatment fraction is large enough to rapidly halt the spread of the
wild-type strain, the resistant strain will not emerge. This is
possible, in part, given our assumption that treatment is
implemented early in the epidemic (i.e., Iw(0) is small). In
conclusion, if c is relatively small and treatment is put in place
later in the epidemic or it cannot surpass r1(wr), then r will
ensure minimal spread of the resistant strain.
We now wish to contrast the effectiveness of r and rmin as a
function of the relative transmissibility w, assuming relatively low
frequency of de novo resistance (c~0:002). Figure 7 shows the FSs
(due to resistant strain (black) and total (blue)) vs. w for r~r and
r~rmin. A treatment regime r
 would ‘‘prioritize’’ the avoidance
of resistance, while compromising the reduction of the overall
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Figure 5. Resistant strain prevalence vs. treatment fraction. Smaller c leads to more abrupt transitions from wild-type to resistant strains.
Larger c renders r ineffective as a treatment regime.
doi:10.1371/journal.pone.0059529.g005
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epidemic; conversely, rmin will, by definition, ‘‘prioritize’’ the
minimization of the total epidemic size, while disregarding the
spread of resistance. As a result, r is more effective than rmin at
halting the spread of resistance in the population, whereas rmin is a
better option to reduce the overall epidemic. Moreover, since
Lr=Lwv0 (see (14)), as w increases, a treatment regime r will
systematically diminish the spread of resistance by reducing the
treated fraction. Consequently, for higher w, r will have minimal
effects on reducing the total epidemic size (compare the diamond
with the horizontal blue line, where no treatment is applied).
Therefore, the decision to use r or rmin as a treatment regime will
mainly depend on how policy makers balance a larger epidemic
produced largely by the wild-type strain, with minimal resistant
cases (using r, for which we have a better biological and
mathematical understanding), versus a smaller overall epidemic
with higher resistance incidence (using rmin).
To summarize, when the fraction of de novo resistant cases and
the relative transmissibility are rather small, r constitutes a useful
quantity for treatment policies in a single epidemic outbreak
provided it can contain the overall epidemic while restraining the
spread of resistance in the population.
Relative transmissibility and non-pharmaceutical
interventions. It is likely that treatment alone cannot com-
pletely quell an emerging epidemic [35]. In such cases, non-
pharmaceutical interventions (e.g., social distancing, case isolation,
travel restrictions) could help to significantly mitigate the extent of
the epidemic [3,8,16]. These can affect the transmissibility of the
wild-type and the resistant strain while maintaining the relative
transmissibility of the latter (w). Here we investigate the
competition dynamics between the wild-type and the resistant
strain as a function of w, and the transmissibility of the wild-type
strain bu (which varies due to non-pharmaceutical interventions)
under different treatment regimes.
The total FS is comprised by the resistant-strain cases (FSres)
plus the wild-type cases (FSw). To determine the dominant strain,
we compare FSres and FSw. Figure 8 shows numerical results of
FSres{FSw in the (bu=cu,w) parameter space (cu fixed). For
instance, if FSres{FSww0 (gray-black region), the resistant strain
is accountable for more cases than the wild-type strain. The wild-
type dominated region is in red.
The resistant strain can only spread in the bu region for which
the wild-type strain significantly spreads: notice in each graph, a
vertical light-red region where only the wild-type strain minimally
spreads, and to its right we see regions of coexistence. The value of
bu defining the split of these two regions, b
1
u, is such that
Rw0 (b
1
u,r)~1; if buvb
1
u(r), the wild-type strain will only generate
few infections and consequently the resistant strain will mainly be
in rare de novo resistant cases. A similar consideration was
presented in Figure 6.
In general, for lower w the resistant strain cannot spread, while
the wild-type strain produces an increasingly larger number of
infections as bu increases. As treatment (r) increases, the resistant-
dominated region shifts to higher values of bu, while expanding the
range of w for which it can significantly spread (darker areas).
These observations suggest that if the wild-type strain features
relatively low transmission, the best strategy to contain both strains
is to treat ‘‘hard and early’’. However, if the transmissibility is
higher and the fitness cost of resistance is low, then this strategy
can have devastating consequences as the resistant strain can infect
a large fraction of the population. This demonstrates the
importance of effective non-pharmaceutical interventions that
could reduce bu.
For larger values of w an interesting process occurs. Starting
from low bu the wild-type dominates. As bu increases – crossing
the ‘‘vertical’’ null isocline where both FSs are equal – the resistant
strain begins to prevail, until crossing the ‘‘slant’’ null isocline
where the wild-type strain starts to regain its dominance. A
possible explanation for this dominance shift is that as the wild-
type strain becomes more transmissible, it depletes the pool of
susceptibles too quickly, leaving the resistant strain with few
individuals to infect once it emerges. However, for even larger w
and high r, increasing bu also increases the FS of the resistant
strain. In this scenario, the relative transmissibility is so high that
even if the wild-type strain can spread rapidly, the resistant strain
will eventually ‘‘catch up’’ and outcompete it.
Figure 6. Final epidemic size of both strains vs. r. (c~0:002 as
asterisks and c~0:02 as diamonds) Vertical dashed lines represent
r(c); higher c, lower r . Note that r is effective in halting the spread
of resistance but not in reducing the total FS. Also, for larger c, r loses
its effectiveness in avoiding the spread of resistance. Other parameters:
bu~0:6, w~0:5.
doi:10.1371/journal.pone.0059529.g006
Figure 7. Final Sizes vs. relative transmissibility for r~r and
r~rmin. The figure shows the effectiveness of r and rmin vs. the
relative transmissibility. For any value of w, r is more effective than rmin
at avoiding the spread of resistance in the population (black diamond
vs. black dashed curves). However, rmin is more efficacious at reducing
the overall epidemic (blue dashed vs. blue diamond). Solid line
corresponds to r~0. Other parameters: bu~0:6, c~0:002:
doi:10.1371/journal.pone.0059529.g007
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Thus, when trying to predict the outcome of the competition
dynamics between wild-type and resistant strains, knowing the
relative transmissibility of the latter is not sufficient. One must also
know the actual value of its transmissibility. In the endemic case,
however, when treatment is fixed, the relative transmissibility
completely determined which strain ultimately dominated
(Figure 2). These considerations complement observations made
in [17].
The Impact of Contact Structure
Two strong simplifications made in our model were to ignore
the complex contact structure of human populations and the
stochastic nature of the transmission and de novo resistance
dynamics. While these assumptions allowed us to obtain closed-
form solutions for effective treatment regimes, the social network
underlying the epidemic process is known to have non-trivial
effects on transmission dynamics [21,22,36,37]. In this section we
use a model equivalent to (1)–(5) that features contact structure
[38] and stochasticity [39]. We again assume c~0:002, and utilize
Monte-Carlo (MC) simulations to assess the effectiveness of r (Eq.
(14)) in single epidemic situations.
To perform MC simulations of the model, we have generated
networks of size N~25|104 with fat-tailed degree distributions
fpkg (distribution of number of contacts per individual, shown in
Figure 9), via the Configuration Model algorithm [40]. For every
generated network, a randomly chosen individual is infected with
the wild-type strain and the dynamics are then simulated in
discrete time:
i. each time step, every susceptible neighbor S of every
infectious individual Ix is infected with probability bxDt;
ii. wild-type infections are treated with probability r, leading to
resistance-conferring mutation with probability c;
iii. each time step every infectious individual Ix recovers with
probability sxDt (with m~0).
Figure 10 shows the variation in the final epidemic size (FS) of
the system due to the contact heterogeneity and the inherent
stochasticity of the disease and pathogen mutation processes. The
worst-case scenarios (the highest FS obtained for a given value of
r) qualitatively follow the same behavior as the ODE model above
(blue curves in Figure 6). More importantly, the predicted optimal
treatment fraction r provides a good approximation to what
could be considered the best treatment plan, yielding the lowest
total FS while halting the spreading of resistance (Figure 10,
greener dots). As in the deterministic case, for rwr, resistance
spreads widely. Hence, when the frequency of de novo cases is small,
the efficacy of the treatment fraction r to minimize both the
epidemic size and the risks of resistance emergence, is robust to
both the heterogeneity of population structure as well as the
stochasticity of transmission and mutation dynamics.
Discussion
The rapid development of an effective vaccine against an
emerging novel influenza virus presents considerable challenges.
Thus, antiviral agents could play a central role as a first-line
defense against emerging epidemics of influenza. The large-scale
use of these drugs could, in turn, select for the evolution of drug-
resistant strains [8], making the strategic distribution of antivirals
essential in quelling the spread of drug-resistance while limiting the
overall epidemic size. In this work we have discussed the influence
of two key parameters on the effectiveness of treatment: the
relative transmissibility of the drug-resistant strain (w), and the
frequency of de novo resistance (c). We extended a previous model
[17] to include demography and performed analytical calculations
of the reproductive numbers, stability of the fixed points, and
conditions for the exclusion or coexistence of resistant and wild-
type pathogen strains.
In the endemic case we found that, depending on the values of
Rr0 (or equivalently w) and c, the optimal treatment regime will be
at intermediate (case (A) for high w and low c ) or more extreme
values (case (B) for low w and high c). Intuitively it is clear that if
the resistant strain is highly transmissible (high w), then treatment
Figure 8. FSres{FSw in the (bu=ªu,w) parameter space. cu is fixed, and r~0:3,0:5,0:7 (left to right). Gray-black regions are dominated by the
resistant strain. As treatment increases the resistant strain 1) benefits from higher wild-strain transmissibility, 2) increases the range of relative
transmissibility for which it can spread, and 3) expands the region in which it can extensively spread (black region).
doi:10.1371/journal.pone.0059529.g008
Figure 9. The fat-tailed degree distribution (contact per
individual) with power-law tail and exponential cut-off. Used
to generate heterogeneous networks for the MC simulations.
doi:10.1371/journal.pone.0059529.g009
Resistant Strain Traits and Effective Treatment
PLOS ONE | www.plosone.org 9 March 2013 | Volume 8 | Issue 3 | e59529
should be moderate in order to limit the selective advantage of
drug-resistant phenotypes. Conversely, if the resistant strain is
weakly transmitted (low w), then more intense treatment regimes
are preferred since resistance-only endemic levels will be relatively
low. These recommendations are valid as long as infections with a
wild-type or a resistant strain represent the same harm to the host
(e.g., strains with similar infectious periods and virulence). In
addition, we also remarked that when c is low, the optimal
treatment regime can be approximated by r. In the single
epidemic case, numerical simulations also suggest that if c and w
are low, r is still a useful quantity when designing treatment
strategies. However, in contrast to the endemic case, knowing the
relative transmissibility of the resistant strain is not enough to
predict the final outcome of the competition between the two
strains. In this case, the strain that successfully spreads first has a
significant impact on which strain infects more individuals during
the epidemic. Our results also indicate that early and high
treatment regimes are most effective at reducing the number of
infections while hindering the rise of resistance, when the
transmissibility of the wild-type strain is relatively low. This
emphasizes the importance of non-pharmaceutical interventions
aimed at reducing the transmission rate of the disease.
Further, we showed that for small c, the parameter r is robust
to the presence of contact heterogeneity and stochasticity, as it still
minimizes both the epidemic size and the risks of resistance
emergence. This reinforces the public health implications of the
effective treatment expressions derived herein.
An interesting similarity across time scales is the impact of the
frequency of de novo resistance on r: as c increases, the
effectiveness of r becomes compromised. While we give
mathematical and biological arguments for this property, the
inherent uncertainty in the empirical values of c make this
observation potentially relevant to the designing of treatment
strategies [8].
Our model, like any other, is not exempt of simplifying
assumptions, or uncertainties about the model parameter values
and transmission dynamics of wild-type and resistant strains. Thus,
rather than providing specific quantitative recommendations for
treatment policies, we emphasize the qualitative character of our
observations. Moreover, we recognize that even if these uncer-
tainties were resolved, we still face ethical issues when deciding to
implement treatment policies based on our recommendations; e.g.,
treat only a certain fraction of those infected if relative transmis-
sibility is high and de novo resistance is unlikely. This is a difficult
case for the public health planner, and the choice is left to them. If
relative transmissibility is low and de novo resistance is more likely,
then our recommendations are less controversial: treat people as
they come in based on their clinical profile. In terms of the
assumptions made in our analysis, we considered that treatment
and de novo resistance happen immediately after infection. In the
Text S1 we present a model that features stage progressions
(treatment and de novo resistance occur at certain rates rather than
instantaneously) and show that its dynamics are analogous to those
presented here (see Figure S1, S2, S3). We also assumed that the
fraction of treated individuals can, with no regard to economic and
social costs, attain any value between 0 and 1, and remain constant
throughout time. This is generally not true as treatment
availability and costs vary with time and socioeconomic context
(models in [5,6,41,42] explore different time-dependent treatment
regimes). We have considered a model with equal birth and death
rates, thus, it may also be important to study the impact of
demographics on the effectiveness of treatment regimes, though
less so in the single epidemic case. We have also excluded
coinfection with both strains, which is known to affect the
evolution of the influenza virus (e.g., viral reassortment [4]), and
could in turn influence the development of drug-resistant
phenotypes. We suspect that accounting for coinfection might
lead to new and interesting dynamics.
Our results shed light on the epidemiological impact of the
interplay between treatment regimes and relative transmissibility
of a strain of influenza resistant to antiviral treatment and the
frequency of de novo resistance, both aspects which are difficult to
assess empirically. These findings could have important implica-
tions for the strategic distribution of antivirals in a population in
response to the emergence of a novel influenza strain.
Supporting Information
Figure S1 Compartmental diagram for the analogous
model.
(EPS)
Figure S2 Comparison of the two models in the endemic
case.
(EPS)
Figure S3 Comparison of the two models in the single
epidemic case.
(EPS)
Figure S4 Transcritical Bifurcation between DFE and
CFP.
(EPS)
Figure S5 Transcritical Bifurcation between RFP and
CFP.
(EPS)
Figure S6 Transcritical Bifurcation between the DFE
and the RFP.
(EPS)
Figure S7 Transcritical Bifurcation between RFP and
CFP.
(EPS)
Figure S8 Stability behavior of the system.
(EPS)
Figure 10. Monte Carlo simulations on a network with
heterogeneous contact structure. (c~0:002). Every point repre-
sents one of over 10,000 simulations on networks of size 250 000, with
color indicating the proportion of resistance in the FS (from black, 100%
wild-type, to green, 100% resistant). r (Eq. (14)) is shown in dashed
black line. The effectiveness of r is robust to stochasticity and
hete rogeneous contac t s t ruc tu res . Other parameter s :
bt~0:3, m~0:3, w~0:5, t~0,bu=cu~0:6, and R
u
0~Sk’Tbu=cu~9:6,
where Sk’T is the average excess degree in the network [39].
doi:10.1371/journal.pone.0059529.g010
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Figure S9 Prevalence as a function of r and w.
(EPS)
Figure S10 I3r (r) for 1vRr0v1=(1{rc) and for
Rr0w1=(1{rc).
(EPS)
Text S1 Analytical derivation of reproduction numbers;
analogous model; analytical derivations regarding the
stability of the system; and analytical derivations
regarding the optimal treatment regimes.
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